CZ20011388A3 - Glykoproteinové hormony obsahující více domén a způsoby jejich pouľití - Google Patents
Glykoproteinové hormony obsahující více domén a způsoby jejich pouľití Download PDFInfo
- Publication number
- CZ20011388A3 CZ20011388A3 CZ20011388A CZ20011388A CZ20011388A3 CZ 20011388 A3 CZ20011388 A3 CZ 20011388A3 CZ 20011388 A CZ20011388 A CZ 20011388A CZ 20011388 A CZ20011388 A CZ 20011388A CZ 20011388 A3 CZ20011388 A3 CZ 20011388A3
- Authority
- CZ
- Czechia
- Prior art keywords
- activity
- subunit
- fsh
- linker
- agonist activity
- Prior art date
Links
- 229940088597 hormone Drugs 0.000 title claims abstract description 100
- 239000005556 hormone Substances 0.000 title claims abstract description 100
- 108090000288 Glycoproteins Proteins 0.000 title claims abstract description 41
- 102000003886 Glycoproteins Human genes 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims description 44
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 23
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims abstract description 15
- 230000000694 effects Effects 0.000 claims description 123
- 125000005647 linker group Chemical group 0.000 claims description 69
- 239000000556 agonist Substances 0.000 claims description 63
- 150000001875 compounds Chemical class 0.000 claims description 56
- 239000005557 antagonist Substances 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 38
- 230000003247 decreasing effect Effects 0.000 claims description 10
- 230000035558 fertility Effects 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 210000000349 chromosome Anatomy 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 230000003362 replicative effect Effects 0.000 claims description 5
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 206010036049 Polycystic ovaries Diseases 0.000 claims description 2
- 230000003042 antagnostic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 208000021267 infertility disease Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 45
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 43
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 43
- 229940028334 follicle stimulating hormone Drugs 0.000 description 43
- 108010073521 Luteinizing Hormone Proteins 0.000 description 42
- 229940040129 luteinizing hormone Drugs 0.000 description 42
- 102000009151 Luteinizing Hormone Human genes 0.000 description 41
- 101800005309 Carboxy-terminal peptide Proteins 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 33
- 235000001014 amino acid Nutrition 0.000 description 32
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 30
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 30
- 150000001413 amino acids Chemical class 0.000 description 30
- 230000027455 binding Effects 0.000 description 25
- 229940015047 chorionic gonadotropin Drugs 0.000 description 24
- 102000005962 receptors Human genes 0.000 description 21
- 108020003175 receptors Proteins 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 230000013595 glycosylation Effects 0.000 description 14
- 238000006206 glycosylation reaction Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 102000023108 LH Receptors Human genes 0.000 description 10
- 108010011942 LH Receptors Proteins 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 9
- 238000002372 labelling Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 230000001588 bifunctional effect Effects 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000003054 hormonal effect Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 238000010188 recombinant method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000008175 FSH Receptors Human genes 0.000 description 3
- 108010060374 FSH Receptors Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- -1 TSH Proteins 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 150000004985 diamines Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 208000000509 infertility Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 102000035824 beta Subunit Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010081485 beta Subunit Follicle Stimulating Hormone Proteins 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000018386 EGF Family of Proteins Human genes 0.000 description 1
- 108010066486 EGF Family of Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 101000893054 Homo sapiens Follitropin subunit beta Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 230000008217 follicular development Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 102000055647 human CSF2RB Human genes 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 231100000503 infertility induction Toxicity 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000012629 purifying agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/175,017 US6635256B1 (en) | 1998-10-19 | 1998-10-19 | Glycoprotein hormone compositions comprising two β subunits and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ20011388A3 true CZ20011388A3 (cs) | 2001-10-17 |
Family
ID=22638493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20011388A CZ20011388A3 (cs) | 1998-10-19 | 1999-10-12 | Glykoproteinové hormony obsahující více domén a způsoby jejich pouľití |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6635256B1 (https=) |
| EP (1) | EP1123315A1 (https=) |
| JP (1) | JP2002533300A (https=) |
| KR (1) | KR20010092418A (https=) |
| CN (1) | CN1330665A (https=) |
| AU (1) | AU774432B2 (https=) |
| BR (1) | BR9914670A (https=) |
| CA (1) | CA2347062A1 (https=) |
| CZ (1) | CZ20011388A3 (https=) |
| HU (1) | HUP0103760A3 (https=) |
| IL (1) | IL142681A0 (https=) |
| NO (1) | NO20011925L (https=) |
| PL (1) | PL347375A1 (https=) |
| TR (1) | TR200101463T2 (https=) |
| WO (1) | WO2000023473A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001333772A (ja) | 2000-04-25 | 2001-12-04 | Washington Univ | 可変性の活性を有する単鎖稔性ホルモン |
| AU2001255624A1 (en) * | 2000-04-25 | 2001-11-07 | Washington University | Single-chain fertility hormones with variable lh activity |
| AU2001283319A1 (en) * | 2000-08-11 | 2002-02-25 | Applied Research Systems Ars Holding N.V. | Glycoproteins and methods of use thereof |
| US6987172B2 (en) * | 2001-03-05 | 2006-01-17 | Washington University In St. Louis | Multifunctional single chain glycoprotein hormones comprising three or more β subunits |
| US7081446B2 (en) * | 2002-01-31 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Long-acting follicle stimulating hormone analogues and uses thereof |
| DE602004030546D1 (de) | 2003-03-04 | 2011-01-27 | Aspenbio Pharma Inc | LH zur Verwendung der Erhaltung einer oder mehreren Schwangerschaften durch Induktion der Bildung des sekundären Gelbkörpers. |
| JP4412989B2 (ja) * | 2003-12-15 | 2010-02-10 | 株式会社日立製作所 | 複数の記憶システムを有するデータ処理システム |
| US20080039372A1 (en) * | 2005-07-21 | 2008-02-14 | The Trustees Of Columbia University In The City Of New York | Human chorionic gonadotropin antagonists and methods to prevent ovarian hyperstimulation |
| US9707276B2 (en) | 2012-12-03 | 2017-07-18 | Merck Sharp & Dohme Corp. | O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues |
| EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| CA3140267A1 (en) | 2019-05-16 | 2020-11-19 | Ceva Sante Animale | Compositions and methods for increasing reproduction performance in non-human mammals using recombinant luteinizing hormone |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0578328B1 (en) | 1983-11-02 | 1999-12-29 | Applied Research Systems ARS Holding N.V. | Material and methods for the production of a heterodimeric human LH with a Met42 Val55 alpha subunit |
| CA1213537A (en) | 1984-05-01 | 1986-11-04 | Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee | Polypeptide expression method |
| US5338835A (en) * | 1989-02-21 | 1994-08-16 | Washington University | CTP-extended form of FSH |
| ES2098261T3 (es) | 1989-02-21 | 1997-05-01 | Univ Washington | Formas modificadas de hormonas reproductoras. |
| WO1991016922A1 (en) | 1990-05-08 | 1991-11-14 | University Of Medicine & Dentistry Of New Jersey | Analogs of glycoprotein hormones having altered immunological characteristics, efficacy and/or receptor specificity |
| CA2097291A1 (en) * | 1990-12-13 | 1992-06-14 | David P. Gearing | Leukemia inhibitory factor receptors |
| WO1992022568A1 (en) * | 1991-06-18 | 1992-12-23 | University Of Medicine & Dentistry Of New Jersey | Analogs of glycoprotein hormones having altered receptor binding specificity and activity and methods for preparing and using same |
| ZA942206B (en) * | 1993-04-01 | 1994-10-31 | Amgen Inc | Biologically active polypeptide fusion dimers |
| DK0751782T3 (da) | 1994-02-18 | 2007-01-29 | Applied Research Systems | Anvendelse af et ikke-neutraliserende antistof, som er specifikt for beta-subunit'en i luteiniserende hormon, til forbedring af fertilitet |
| PT725795E (pt) * | 1994-08-12 | 2004-05-31 | Univ Washington | Formas de cadeia simples do quarteto de hormonas glicoproteicas |
| US6103501A (en) * | 1997-11-17 | 2000-08-15 | Washington University | Single chain glycoprotein hormones comprising two β and one α subunits and recombinant production thereof |
-
1998
- 1998-10-19 US US09/175,017 patent/US6635256B1/en not_active Expired - Lifetime
-
1999
- 1999-10-12 HU HU0103760A patent/HUP0103760A3/hu unknown
- 1999-10-12 PL PL99347375A patent/PL347375A1/xx not_active Application Discontinuation
- 1999-10-12 BR BR9914670-3A patent/BR9914670A/pt not_active Application Discontinuation
- 1999-10-12 IL IL14268199A patent/IL142681A0/xx unknown
- 1999-10-12 WO PCT/US1999/023555 patent/WO2000023473A1/en not_active Ceased
- 1999-10-12 TR TR2001/01463T patent/TR200101463T2/xx unknown
- 1999-10-12 EP EP99954814A patent/EP1123315A1/en not_active Ceased
- 1999-10-12 JP JP2000577198A patent/JP2002533300A/ja active Pending
- 1999-10-12 CZ CZ20011388A patent/CZ20011388A3/cs unknown
- 1999-10-12 KR KR1020017004919A patent/KR20010092418A/ko not_active Ceased
- 1999-10-12 CN CN99813541A patent/CN1330665A/zh active Pending
- 1999-10-12 CA CA002347062A patent/CA2347062A1/en not_active Abandoned
- 1999-10-12 AU AU11072/00A patent/AU774432B2/en not_active Ceased
-
2001
- 2001-04-19 NO NO20011925A patent/NO20011925L/no not_active Application Discontinuation
-
2003
- 2003-08-21 US US10/647,088 patent/US7442376B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NO20011925D0 (no) | 2001-04-19 |
| US6635256B1 (en) | 2003-10-21 |
| PL347375A1 (en) | 2002-04-08 |
| TR200101463T2 (tr) | 2001-10-22 |
| AU774432B2 (en) | 2004-06-24 |
| JP2002533300A (ja) | 2002-10-08 |
| HUP0103760A2 (hu) | 2002-01-28 |
| US20040220088A1 (en) | 2004-11-04 |
| NO20011925L (no) | 2001-06-18 |
| EP1123315A1 (en) | 2001-08-16 |
| WO2000023473A1 (en) | 2000-04-27 |
| KR20010092418A (ko) | 2001-10-24 |
| HUP0103760A3 (en) | 2003-09-29 |
| US7442376B2 (en) | 2008-10-28 |
| AU1107200A (en) | 2000-05-08 |
| BR9914670A (pt) | 2002-02-05 |
| IL142681A0 (en) | 2002-03-10 |
| CA2347062A1 (en) | 2000-04-27 |
| CN1330665A (zh) | 2002-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2308571C (en) | Single-chain bifunctional glycoprotein hormones | |
| US6242580B1 (en) | Single-chain forms of the glycoprotein hormone quartet | |
| US6987172B2 (en) | Multifunctional single chain glycoprotein hormones comprising three or more β subunits | |
| IL114859A (en) | Glycoproteins, pharmaceutical and veterinary compositions containing the same and methods for the production thereof | |
| EP0725795B1 (en) | Single-chain forms of the glycoprotein hormone quartet | |
| CZ20011388A3 (cs) | Glykoproteinové hormony obsahující více domén a způsoby jejich pouľití | |
| US5883073A (en) | Single-chain double-alpha peptide | |
| US6689365B1 (en) | Single-chain fertility hormones with fsh and LH activity | |
| JP2009050278A (ja) | 糖タンパク質ホルモンカルテットの一本鎖形態 | |
| EP1276765B1 (en) | Single-chain fertility hormones with variable lh activity | |
| MXPA01003947A (en) | Multiple domain glycoprotein hormones and methods of using | |
| MXPA00004761A (en) | Single-chain bifunctional glycoprotein hormones |